Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
Neoadjuvant vinorelbine/epirubicin compared well with adriamycin/cyclophosphamide
November 10th, 2005
The efficacy of neoadjuvant vinorelbine/epirubicin (VE) chemotherapy compared well to adriamycin/cyclophosphamide (AC) in cases of operable breast cancer. "Vinorelbine is active and well tolerated against advanced breast cancer but there are no published efficacy studies in early breast cancer. We have therefore carried out a randomized phase III neoadjuvant trial in operable breast cancer," scientists reported in the journal Annals of Oncology. "Patients with {{>=}}3 cm operable breast carcinoma were randomized to receive either vinorelbine 25 mg/m2 on days 1 and 8 and epirubicin 60 mg/m2 on day 1, 3 weekly for 6...
Source: Women's Health Weekly (2005-11-10)
|
